SCHEMBL4475112

SCHEMBL4475112

Cc1ccc(-c2ccc(C34C=CCN(CC3)C4)cn2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 1/20 0.37
KDM1A O60341 1/20 0.36
ALOX5AP P20292 1/20 0.35
AURKA O14965 1/20 0.30
ABL1 P00519 1/20 0.30
NTRK1 P04629 1/20 0.30
LCK P06239 1/20 0.30
CSF1R P07333 1/20 0.30
RET P07949 1/20 0.30
MET P08581 1/20 0.30
PDGFRB P09619 1/20 0.30
PIM1 P11309 1/20 0.30
PDGFRA P16234 1/20 0.30
FLT3 P36888 1/20 0.30
MAPK8 P45983 1/20 0.30
CDK8 P49336 1/20 0.30
MAP2K1 Q02750 1/20 0.30
MAP4K2 Q12851 1/20 0.30
ROCK1 Q13464 1/20 0.30
NTRK3 Q16288 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4461401 0.89 ALOX5AP (0.31) KDM1AALOX5AP
SCHEMBL4470449 0.88 SLC6A2 (0.38) KDM1A
SCHEMBL4463819 0.88 HSD11B1 (0.38) CHRNA7
SCHEMBL4463735 0.87 RXFP1 (0.39) CHRNA7
Bromide SCHEMBL4466117 0.86 HSD11B1 (0.37) CHRNA7
SCHEMBL4463770 0.86 ALOX5AP (0.34) ALOX5APROCK1
SCHEMBL4465250 0.86 KDM1A (0.40) KDM1AALOX5AP
SCHEMBL1482889 0.83 ALOX5AP (0.38) KDM1AALOX5APPIM1MAPK14
Bromide SCHEMBL4267971 0.82 ALOX5AP (0.38) KDM1AALOX5APPIM1MAPK14
SCHEMBL5216772 0.82 FYN (0.38) KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7585974-B2 Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, their preparation and their therapeutic application SANOFI-AVENTIS (FR) 2009-09-08 US claimed
US-20070185137-A1 Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, their preparation and their therapeutic application SANOFI-AVENTIS (FR) 2007-08-09 US claimed
EP-1465893-B1 DERIVATIVES OF 5-(PYRIDIN-3-YL)-1-AZABICYCLO (3.2.1) OCTANE, THE PREPARATION THEREOF AND THE APPLICATION OF SAME IN THERAPEUTICS SANOFI AVENTIS (FR) 2007-02-28 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185137-A1 Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, their preparation and their therapeutic application PAICS, CYC1, AADAC CHRNA7 407/4885KDM1A 1225/4885ALOX5AP 644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.